Clinical treatment options oriented to the endotype of chronic rhinosinusitis.
10.13201/j.issn.2096-7993.2023.11.009
- Author:
Yutong SIMA
1
;
Yan ZHAO
1
;
Jian JIAO
1
;
Xiangdong WANG
1
;
Luo ZHANG
1
Author Information
1. Department of Otolaryngology Head and Neck Surgery，Beijing TongRen Hospital，Capital Medical University，Beijing，100730.
- Publication Type:Journal Article
- Keywords:
biologics;
chronic rhinosinusitis;
endotype;
eosinophil;
type 2 inflammation
- MeSH:
Humans;
Rhinitis/therapy*;
Nasal Polyps/diagnosis*;
Quality of Life;
Sinusitis/diagnosis*;
Eosinophilia;
Chronic Disease
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2023;37(11):902-908
- CountryChina
- Language:Chinese
-
Abstract:
Chronic rhinosinusitis（CRS） is an inflammatory disease involving the mucosa of the nasal and paranasal sinuses for more than 12 weeks and can be classified as CRS with nasal polyp（CRSwNP） and CRS without nasal polyp（CRSsNP） depending on the phenotype. Clinical treatments reveal significant differences in disease prognosis and improvement in quality of life in patients with the same clinical phenotype. Inflammatory cells infiltration and inflammatory mediators are important factors driving CRS endotypes. In particular, CRS with predominantly eosinophilic infiltration and type 2 CRS present severe clinical symptoms, comorbidities, and high recurrence rates. CRS endotype-oriented treatment methods may better contribute to improving patient prognosis and quality of life. This article summarizes the current progress of CRS endotype research and reviews the endotype-oriented treatment options.
